Symbol: OTCQB:XPHYF
- Outstanding Shares: 68,461,579
- Float: 49,497,972
OTCQB:XPHYF is involved with what could be a POWERFUL tool in the COVID arsenal.
This TRI-LISTED BioTech Stock in the US, Canada, and Germany, also has its hands in some of the most cutting-edge industries today from CBD, THC, and even Psychedelics!
XPhyto Therapeutics Corp. (XPHYF) is a Bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.
And now the company had MAJOR BREAKING NEWS out yesterday that could certainly turn heads on the Street...
Subscribe to Receive Client Updates Delivered Straight To Your Inbox
Recent News
- InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp. – June 17, 2021
- XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies – June 15, 2021
- XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies – June 8, 2021
- XPhyto Rapid Point-of-Care COVID-19 PCR Test Offered for Sale in Germany – May 20, 2021
- XPhyto Provides Update on Drug Formulation and Development Business – May 13, 2021
- XPhyto Establishes Proof of Concept Station for Point-of-Care 25-minute COVID-19 PCR Test in Germany – May 7, 2021
- InvestorBrandNetwork Announces Gamechangers LIVE Interview with XPhyto Therapeutics Corp. CEO and Director Hugh Rogers – May 6, 2021
- XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test – April 28, 2021
- XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test – April 21, 2021
- XPhyto adds Top-Level Executive Talent to its Global Operations – April 20, 2021
- XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test – March 29, 2021
- XPhyto announces European Approval for 25 Minute COVID-19 PCR Test – March 18, 2021
- InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. – March 12, 2021
- XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test – March 10, 2021
- XPhyto Completes Corporate Rebranding and Launches New Website – March 4, 2021
- XPhyto Provides Updated Comments on Promotional and Marketing Activity – Feb. 26, 2021
- XPhyto Places First Order for 25-Minute COVID-19 RT-PCR Tests – Feb. 24, 2021
- XPhyto Builds Commercial Team to Launch 25-Minute Covid-19 RT-PCR Test – Feb. 22, 2021
- XPhyto European CE-IVD Application for 25-Minute Covid-19 RT-PCR Test – Feb. 17, 2021
Emerging Markets Report
Must Read OTC Markets/SEC policy on stock promotion and investor protection
Disclaimer
Emerging Markets is under contract to be paid 150,000 dollars by XPhyto Therapeutics Corp. | Please read our full disclaimer
-
-
Florida Office
Emerging Markets Consulting, LLC
390 North Orange Avenue, Suite 2300
Orlando, FL, US, 32801Phone: 407.340.0226
Fax: 352.429.0961 -
Vancouver Office
Emerging Markets Consulting, LLC
600-890 West Pender Street
Vancouver, BC V6C 1J8, CanadaPhone: 778.370.5653
Fax: 778.488.9581 -
Alabama Office
Emerging Markets Consulting, LLC
640-350 N McKenzie St.
Foley, Alabama 36535New York Office
Emerging Markets Consulting, LLC
48 Wall Street Suite 1100
New York, New York 10005Phone: 407-340-0226
-
Coin Payments Accepted
EMC accepts payments in the following cryptocurrencies
